Sha Fu

2.4k citations

77 papers · 1.2k · h-index 22

Impact in

Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Nephrology top 5%

Papers in

Oncology 16
- Cancer Immunotherapy and Biomarkers 7
Molecular Biology 14

Co-authors: Haiyun Wang (10 shared papers)Jian‐Yong Shao (10 shared papers)Shuhan Sun (1 shared paper)Jian Zhang (1 shared paper)Anping Xu (9 shared papers)Yixin Zhou (17 shared papers)Xuanye Zhang (17 shared papers)Shaodong Hong (18 shared papers)
Journals: Frontiers in Immunology (5 papers)Lung Cancer (4 papers)BMC Nephrology (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)Journal of Translational Medicine (3 papers)
Partner nations: China United States Hong Kong

In The Last Decade

Sha Fu

75 papers receiving 1.2k citations

Peers

Countries citing papers authored by Sha Fu

Since Specialization

Citations

This map shows the geographic impact of Sha Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sha Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sha Fu more than expected).

Fields of papers citing papers by Sha Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sha Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sha Fu. The network helps show where Sha Fu may publish in the future.

Co-authors

The 25 scholars most cited alongside Sha Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sha Fu Line = papers co-authored together Sha Fu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Inflammasome activation has an important role in the development of spontaneous colitis Mucosal Immunology ·Jian Zhang, Sha Fu, Shuhan Sun, Z Li, Binao Guo	2014	107
2	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis Journal for ImmunoTherapy of Cancer ·Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang	2018	85
3	Knockdown of miR-214 Promotes Apoptosis and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma PLoS ONE ·Zi-Chen Zhang, Yang Yang Li, Haiyun Wang, Sha Fu, Xiao-Pai Wang, Mu‐Sheng Zeng, Yi Zeng, Jian-Yong Shao	2014	56
4	TGF-β-Induced CD8+CD103+ Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells Frontiers in Immunology ·Haowen Zhong, Ya Liu, Zhenjian Xu, Peifeng Liang, Hui Yang, Xiao Zhang, Jun Zhao, Junzhen Chen, Sha Fu, Ying Tang, Jun Lv, Julie Wang, Nancy J. Olsen, Anping Xu, Song Guo Zheng	2018	50
5	Profiling Plasma MicroRNA in Nasopharyngeal Carcinoma with Deep Sequencing Clinical Chemistry ·Haiyun Wang, Li‐Xu Yan, Qiong Shao, Sha Fu, Zi-Chen Zhang, Weimin Ye, Yi-Xin Zeng, Jian‐Yong Shao	2014	47
6	miR-20a-5p is enriched in hypoxia-derived tubular exosomes and protects against acute tubular injury Clinical Science ·Wenjuan Yu, Honghui Zeng, Junzhe Chen, Sha Fu, Qiuyan Huang, Yanchun Xu, Anping Xu, (unknown), Ying Tang	2020	43
7	Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19 BMC Nephrology ·Zhenjian Xu, Ying Tang, Qiuyan Huang, Sha Fu, Xiaomei Li, Baojuan Lin, Anping Xu, Junzhe Chen	2021	38
8	Smad7 protects against acute kidney injury by rescuing tubular epithelial cells from the G1 cell cycle arrest Clinical Science ·Sha Fu, Ying Tang, Xiao Ru Huang, Min Feng, An P. Xu, Hui Y. Lan	2017	38
9	The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population Immunity & Ageing ·Ying Tang, Peifen Liang, Junzhe Chen, Sha Fu, Bo Liu, Min Feng, Baojuan Lin, Benjamin Lee, Anping Xu, Hui Y. Lan	2018	36
10	Crosstalk between hepatitis B virus X and high‐mobility group box 1 facilitates autophagy in hepatocytes Molecular Oncology ·Sha Fu, Juan Wang, Xingwang Hu, Rongrong Zhou, Yongming Fu, Daolin Tang, Rui Kang, Yan Huang, Lun‐Quan Sun, Ning Li, Xuegong Fan	2018	31
11	MicroRNA-30a promotes invasiveness and metastasis in vitro and in vivo through epithelial–mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients Experimental Biology and Medicine ·Haiyun Wang, Yang Yang Li, Sha Fu, Xiao-Pai Wang, Ma-Yan Huang, Xiao Zhang, Qiong Shao, Ling Deng, Mu‐Sheng Zeng, Yi‐Xin Zeng, Jian‐Yong Shao	2014	30
12	Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC JAMA Network Open ·Yixin Zhou, Anlin Li, Hui Yu, Yuhong Wang, Xuanye Zhang, Huijuan Qiu, Wei Du, Linfeng Luo, Sha Fu, Li Zhang, Shaodong Hong	2024	28
13	Nuclear DAMP complex-mediated RAGE-dependent macrophage cell death Biochemical and Biophysical Research Communications ·Ruochan Chen, Sha Fu, Xuegong Fan, Michael T. Lotze, Herbert J. Zeh, Daolin Tang, Rui Kang	2015	28
14	Pittsburgh Sleep Quality Index score predicts all-cause mortality in Chinese dialysis patients International Urology and Nephrology ·Qianqian Han, Bo Liu, Shu‐Min Lin, Jiajia Li, Peifen Liang, Sha Fu, Guiqiong Zheng, Suqiong Yang, Бин Ли, Qiongqiong Yang	2021	27
15	High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR Journal of Translational Medicine ·Fang Wang, Sha Fu, Qiong Shao, Yanbin Zhou, Xiao Zhang, Xu Zhang, Cong Xue, Jian-Guang Lin, Li-Xia Huang, Li Zhang, Wei-Min Zhang, Jian-Yong Shao	2013	27
16	First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma Lung Cancer ·Zuan Lin, Sha Fu, Yixin Zhou, Xuanye Zhang, Chen Chen, Li-na He, Haifeng Li, Yuhong Wang, Tao Chen, Li Zhang, Shaodong Hong	2019	26
17	Oncogene mutational profile in nasopharyngeal carcinoma OncoTargets and Therapy ·Jian‐Yong Shao, Zi-Chen Zhang, Sha Fu, Fang Wang, Haiyun Wang, Yi-Xin Zeng	2014	26
18	Transforming Growth Factor–Induced Protein Promotes NF-κB–Mediated Angiogenesis during Postnatal Lung Development American Journal of Respiratory Cell and Molecular Biology ·Min Liu, Cristiana Iosef, Shailaja Rao, Racquel Domingo-Gonzalez, Sha Fu, Paige Snider, Simon J. Conway, Gray Umbach, Sarah C. Heilshorn, Ruby E. Dewi, Mar Janna Dahl, Donald M. Null, Kurt H. Albertine, Cristina M. Alvira	2020	24
19	STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC Journal of Thoracic Oncology ·Anlin Li, Yuanyuan Wang, Zhixin Yu, Zihui Tan, Lina He, Sha Fu, Mengting Shi, Wei Du, Linfeng Luo, Zhichao Li, Jiaqing Liu, Yixin Zhou, Wenfeng Fang, Yunpeng Yang, Li Zhang, Shaodong Hong	2023	22
20	Down-Regulation of C9orf86 in Human Breast Cancer Cells Inhibits Cell Proliferation, Invasion and Tumor Growth and Correlates with Survival of Breast Cancer Patients PLoS ONE ·Yang Yang Li, Sha Fu, Xiao-Pai Wang, Haiyun Wang, Mu‐Sheng Zeng, Jian‐Yong Shao	2013	22

About Sha Fu

Sha Fu is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Epidemiology, having authored 77 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), MicroRNA in disease regulation (5 papers), Systemic Lupus Erythematosus Research (4 papers), Cancer-related molecular mechanisms research (4 papers), Hepatitis B Virus Studies (3 papers), Head and Neck Cancer Studies (3 papers) and Heart Failure Treatment and Management (3 papers). The work is most often cited by research in Cancer Research (220 citations), Nephrology (81 citations), Oncology (284 citations), Immunology (207 citations) and Otorhinolaryngology (30 citations). Sha Fu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Haiyun Wang, Jian‐Yong Shao, Shuhan Sun, Jian Zhang, Anping Xu, Yixin Zhou, Xuanye Zhang, Shaodong Hong, Junzhe Chen and Ying Tang. Their work appears in journals such as Frontiers in Immunology, Lung Cancer, BMC Nephrology, Journal for ImmunoTherapy of Cancer and Journal of Translational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Sha Fu

Impact in

Papers in i

In The Last Decade

Sha Fu

Peers

Countries citing papers authored by Sha Fu

Fields of papers citing papers by Sha Fu

All Works

About Sha Fu

Explore authors with similar magnitude of impact

Papers in